According to the research report, the global precision oncology market size is expected to touch USD 258.35 Billion by 2032, from USD 100.06 Billion in 2022, growing with a significant CAGR of 9.95% from 2023 to 2032.
The precision oncology report offers a comprehensive study of the current state expected at the major drivers, market strategies, and key vendors’ growth. The report presents energetic visions to conclude and study the market size, market hopes, and competitive surroundings. The research also focuses on the important achievements of the market, research & development, and regional growth of the leading competitors operating in the market. The current trends of the global precision oncology in conjunction with the geographical landscape of this vertical have also been included in this report.
The report offers intricate dynamics about different aspects of the global precision oncology market, which aids companies operating in the market in making strategic development decisions. The study also elaborates on significant changes that are highly anticipated to configure growth of the global precision oncology during the forecast period. It also includes a key indicator assessment that highlights growth prospects of this market and estimates statistics related to growth of the market in terms of value (US$ Mn) and volume (tons).
Sample Link @ https://www.precedenceresearch.com/sample/2904
Report Scope of the Precision Oncology Market:
| Report Coverage | Details |
| Market Size in 2023 | USD 110.02 Billion |
| Market Size by 2032 | USD 258.35 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 9.95% |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Product, By Cancer Type, and By End-Use |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America and Middle East & Africa |
This study covers a detailed segmentation of the global precision oncology market, along with key information and a competition outlook. The report mentions company profiles of players that are currently dominating the global precision oncology market, wherein various developments, expansions, and winning strategies practiced and implemented by leading players have been presented in detail.
Key Players
- Thermo Fisher Scientific, Inc.
- Invitae Corporation
- Illumina, Inc.
- Myriad Genetics, Inc.
- AstraZeneca
- Rain Oncology Inc.
- Strata Oncology, Inc.
- Repare Therapeutics
- Relay Therapeutics
- Exscientia
- Exact Sciences Corporation
Market Segmentation
By Product
- Diagnostics
- Therapeutics
By Cancer Type
- Breast cancer
- Colorectal cancer
- Lung cancer
- Blood Cancer
- Prostate Cancer
- Others
By End-Use
- Pharmaceutical & Biotechnology Companies
- Hospitals & Diagnostic Laboratories
- Healthcare Data Companies
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Research Methodology
The research methodology adopted by analysts for compiling the global precision oncology report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.
During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.
For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global precision oncology market.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Precision Oncology Market
5.1. COVID-19 Landscape: Precision Oncology Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Precision Oncology Market, By Product
8.1. Precision Oncology Market, by Product, 2023-2032
8.1.1 Diagnostics
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Therapeutics0
8.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Precision Oncology Market, By Cancer Type
9.1. Precision Oncology Market, by Cancer Type, 2023-2032
9.1.1. Breast cancer
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Colorectal cancer
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Lung cancer
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Blood Cancer
9.1.4.1. Market Revenue and Forecast (2020-2032)
9.1.5. Prostate Cancer
9.1.5.1. Market Revenue and Forecast (2020-2032)
9.1.6. Others
9.1.6.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Precision Oncology Market, By Cancer Type
10.1. Precision Oncology Market, by Cancer Type, 2023-2032
10.1.1. Pharmaceutical & Biotechnology Companies
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Hospitals & Diagnostic Laboratories
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Healthcare Data Companies
10.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Precision Oncology Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Product (2020-2032)
11.1.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.1.3. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Product (2020-2032)
11.1.4.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.1.4.3. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Product (2020-2032)
11.1.5.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.1.5.3. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Product (2020-2032)
11.2.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.2.3. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Product (2020-2032)
11.2.4.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.2.4.3. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Product (2020-2032)
11.2.5.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.2.5.3. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Product (2020-2032)
11.2.6.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.2.6.3. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Product (2020-2032)
11.2.7.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.2.7.3. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Product (2020-2032)
11.3.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.3.3. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Product (2020-2032)
11.3.4.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.3.4.3. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Product (2020-2032)
11.3.5.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.3.5.3. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Product (2020-2032)
11.3.6.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.3.6.3. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Product (2020-2032)
11.3.7.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.3.7.3. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Product (2020-2032)
11.4.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.4.3. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Product (2020-2032)
11.4.4.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.4.4.3. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Product (2020-2032)
11.4.5.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.4.5.3. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Product (2020-2032)
11.4.6.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.4.6.3. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Product (2020-2032)
11.4.7.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.4.7.3. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Product (2020-2032)
11.5.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.5.3. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Product (2020-2032)
11.5.4.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.5.4.3. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Product (2020-2032)
11.5.5.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.5.5.3. Market Revenue and Forecast, by Cancer Type (2020-2032)
Chapter 12. Company Profiles
12.1. Thermo Fisher Scientific, Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Invitae Corporation
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Illumina, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Myriad Genetics, Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. AstraZeneca
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Rain Oncology Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Strata Oncology, Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Repare Therapeutics
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Relay Therapeutics
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Exscientia
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
0 Comments